ESH AL 2026 | The current role of inotuzumab ozogamicin in the ALL treatment landscape
Wendy Stock, MD, University of Chicago Medical Center, Chicago, IL, discusses the current use of inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia (ALL), particularly in older adult populations, where it is being incorporated into frontline therapy to overcome treatment resistance and reduce toxicities. This interview took place at the 5th How to Diagnose and Treat: Acute Leukemias meeting of the European School of Hematology (ESH AL) in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You know, inotuzumab ozogamicin at this moment is only approved for relapsed treatment of relapsed CD22-positive ALL. But I think a huge number of trials now, especially focused on the older adult population, have incorporated inotuzumab ozogamicin into frontline therapy as a way of overcoming treatment resistance and reducing treatment-related toxicities. So I think many of our current older adult trials in ALL are now incorporating inotuzumab ozogamicin into frontline treatment to minimize the toxicity and to overcome some of the treatment resistance that we’ve seen in older adult populations...
You know, inotuzumab ozogamicin at this moment is only approved for relapsed treatment of relapsed CD22-positive ALL. But I think a huge number of trials now, especially focused on the older adult population, have incorporated inotuzumab ozogamicin into frontline therapy as a way of overcoming treatment resistance and reducing treatment-related toxicities. So I think many of our current older adult trials in ALL are now incorporating inotuzumab ozogamicin into frontline treatment to minimize the toxicity and to overcome some of the treatment resistance that we’ve seen in older adult populations. For the younger adult population, although we are testing actively inotuzumab ozogamicin in the frontline, we do not have yet a safe or effective, we have an effective dose. We don’t have a safe dose. And so we really are retooling our most recent study where we were trying to incorporate inotuzumab ozogamicin into the frontline to reduce the number of cycles to just one and then we will be moving forward with a pilot trial that uses that one cycle of inotuzumab ozogamicin and also incorporates blinatumumab into the frontline setting in younger adults with ALL.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
